Roelf Datema

52159710, Jun 1, 1993

Jul 2, 1991

7/726738

Roelf Datema - Cheshire CT
Kristina B. Gotthammar - Saltsjo-Boo, SE
Karl N. G. Johansson - Enhorna, SE
Zsuzsanna M. I. Kovacs - Pietra Ligure, IT
Bjorn G. Lindborg - Alvsjo, SE
Goran B. Stening - Sodertalje, SE
Bo F. berg - Uppsala, SE

Medivir AB - Stockholm

A61K 3170
C07H 1700

514 49

Use of a compound of the formula ##STR1## wherein A is. beta. -2'-deoxy-D-ribofuranosyl or. beta. -D-arabinofuranosyl; R. sup. 1 is hydroxy or amino; R. sup. 2 is cycloalkyl or alkyl-substituted cycloalkyl containing 1-5 carbon atoms; saturated or unsaturated, straight or branched alkyl containing 1-5 carbon atoms which may be unsubstituted or substituted with halogen, hydroxy, mercapto, trifluoroalkyl or difluoroalkyl containing 1-3 carbon atoms, phenoxy or alkoxy containing 1-3 carbon atoms; phenyl or phenylalkyl containing 1-3 carbon atoms in the alkyl part, or a physiologically acceptable salt thereof, for manufacture of a medicament for therapeutic or prophylactic control or treatment of retrovirus, especially HIV, or hepatitis B virus infections in animal and man and to a method of such treatment.

54099064, Apr 25, 1995

Apr 1, 1993

8/041165

Roelf Datema - Cheshire CT
Zsuzanna M. I. Kovacs - Pietra Ligure, IT
Karl N. G. Johansson - Enhorna, SE
Bjorn Lindborg - Alvsjo, SE
Goran B. Stening - Sodertalje, SE
Bo. F. Oberg - Uppsala, SE

Medivir AB - Huddinge

A61K 31505

514 49

A compound of the formula ##STR1## wherein the radicals A, X, R. sup. 1, R. sup. 2 and R. sup. 3 are defined as follows: A: ##STR2## X: (a) O (b) S (c) CH. sub. 2 R. sup. 1 : H; alkyl containing 1-3 carbon atoms; --CH. dbd. CH. sub. 2 ; --CH. dbd. CH--CH. sub. 3 ; --CH. sub. 2 --CH. dbd. CH. sub. 2 ; ##STR3## --C. tbd. CH p1 R. sup. 2 : H; or R. sup. 2 constitutes together with R. sup. 3 a carbon--carbon bond R. sup. 3 : H; F; Cl; Br; I; N. sub. 3 ; CN; C. tbd. CH; OH; OCH. sub. 3 ; CH. sub. 2 OH; and when R. sup. 3 is F; Cl; Br; I; N. sub. 3 ; CN; C. tbd. CH; OH; OCH. sub. 3 or CH. sub. 2 OH it may have either the cis-configuration or trans-configuration relative to the hydroxymetyl function at position 4', or R. sup. 3 constitutes together with R. sup. 2 a carbon--carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV virus infections.

55654614, Oct 15, 1996

Apr 3, 1995

8/416539

Bj orn G. Lindborg - Alvsj o, SE
Roelf Datema - Cheshire CT
Karl N. G. Johansson - Enh orna, SE
Bo F. Oberg - Uppsala, SE

Medivir AB - Huddinge

A61K 3152
C07D47318
C07D47332
C07D47316

514262

The present invention is directed to a method of treating an HIV infection in a host in need of such treatment which comprises administering an effective anti-HIV amount of a compound having the formula ##STR1## wherein: R. sup. 1 is hydrogen, hydroxyl; R. sup. 2 is amino; R. sup. 3 and R. sup. 4 are independently selected from hydroxyl or an ester residue of said hydroxyl group derived from R. sup. 6 COOH, wherein R. sup. 6 is hydrogen, or C. sub. 1 -C. sub. 3 alkyl; and n is 1; or a pharmaceutically acceptable salt thereof.

52159701, Jun 1, 1993

Nov 20, 1991

7/794704

Roelf Datema - Cheshire CT
Zsuzanna M. I. Kovacs - Pietra Ligure, IT
Karl N. G. Johansson - Enhorna, SE
Bjorn G. Lindborg - Alvsjo, SE
Goran B. Stening - Sodertalje, SE
Bo F. Oberg - Uppsala, SE

Medivir AB - Huddinge

A61K 3170

514 49

A compound of the formula ##STR1## wherein the radicals A, X, R. sup. 1, R. sup. 2 and R. sup. 3 are defined as follows: ##STR2## R. sup. 2 : H; or R. sup. 2 constitutes together with R. sup. 3 with a carbon - carbon bond R. sup. 3 : H; F; Cl; Br; I; N. sub. 3 ; CN; C. tbd. CH; OH; OCH. sub. 3 ; CH. sub. 2 OH; and when R. sup. 3 is F; Cl; Br; I; N. sub. 3 ; CN; C. tbd. CH; OH; OCH. sub. 3 or CH. sub. 2 OH it may have either the cis-configuration or trans-configuration relative to the hydroxymethyl function at position 4', or R. sup. 3 constitutes together with R. sup. 2 a carbon - carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV infections.

52848370, Feb 8, 1994

Dec 26, 1990

7/601693

Bjorn G. Lindborg - Alvsjo, SE
Roelf Datema - Cheshire CT
Karl N. G. Johansson - Enhorna, SE
Bo F. berg - Uppsala, SE

Medivir AB - Huddinge

C07D47318
C07D47332
C07D47334
A61K 3152

514 81

Antivirally active compounds of formula (I), wherein R. sup. 1 is hydrogen, hydroxy, mercapto or amino; R. sup. 2 is hydrogen, hydroxy, fluoro, chloro or amino; R. sup. 3 and R. sup. 4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R. sup. 3 together with R. sup. 4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R. sup. 2 is amino and R. sup. 3 and R. sup. 4 are hydroxy R. sup. 1 is not hydroxy and in addition, when n=1, R. sup. 1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS. ##STR1##.

56566174, Aug 12, 1997

Jun 7, 1995

8/476348

Bjorn Gunnar Lindborg - Alvsjo, SE
Roelf Datema - Cheshire CT
Karl Nils Gunnar Johansson - Enhorna, SE
Bo Fredrik Oberg - Uppsala, SE

Medivir AB - Huddinge

A61K 3152
A61K 31675
C07F 96561
C07D47318

514 81

Antivirally active compounds of formula (I), wherein R. sup. 1 is hydrogen, hydroxy, mercapto or amino; R. sup. 2 is hydrogen, hydroxy, fluoro, chloro or amino; R. sup. 3 and R. sup. 4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R. sup. 3 together with R. sup. 4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R. sup. 2 is amino and R. sup. 3 and R. sup. 4 are hydroxy, R. sup. 1 is not hydroxy and in addition, when n=1, R. sup. 1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS. ##STR1##.